PT-141 (Bremelanotide)
Price on application
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist. It is the only melanocortin-based peptide FDA-approved for treating hypoactive sexual desire disorder, acting centrally on the nervous system rather than the vascular system.
Research Profile
PT-141 (Bremelanotide) is a cyclic lactam analog of alpha-melanocyte-stimulating hormone (α-MSH) that acts as a non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R, with primary activity at MC4R. Unlike PDE5 inhibitors that act on vascular smooth muscle, PT-141 works through central nervous system pathways to influence sexual arousal and desire. It received FDA approval in 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. In research, it continues to be studied for broader melanocortin-mediated effects including appetite regulation, inflammation modulation, and neuroprotection.
Technical Details
- Chemical Formula
- C50H68N14O10
- Synonyms
- Bremelanotide, Vyleesi, PT-141
- Molecular Weight
- 1025.18 g/mol
- CAS Number
- 189691-06-3
- PubChem ID
- 9941379
- Sequence
- Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
- Appearance
- Lyophilized White Powder
- Purity
- >99% (HPLC Verified)
- Shelf Life
- 36 months (Store at -20°C)